Ariana Pelosci

TAR-200 plus cetrelimab did not yield significant results vs chemoradiation in muscle-invasive bladder cancer.

A new surgical option of uterine transposition may help preserve fertility for women who have cancers of the pelvic region.

Results from KEYNOTE-671 show an improvement in OS when a neoadjuvant/adjuvant regimen of pembrolizumab was used to treat patients with NSCLC.

Results from the INNATE trial showed the use of sotigalimab to be a safe and efficacious regimen for patients with rectal cancer.

Findings from the phase 3 CheckMate 77T trial support the approval of nivolumab plus chemotherapy for resectable NSCLC.

Efficacy findings were enhanced when 177Lu-Dotatate was used to treat patients with grade II/III recurrent meningioma.

Hypofractionated postmastectomy radiotherapy was noninferior to standard radiation in patients who underwent a mastectomy.

Results from the ARANOTE trial support the supplemental new drug application for darolutamide/ADT in metastatic hormone-sensitive prostate cancer.

A subgroup analysis from the PERSEUS trial showed sustained PFS benefit in patients with newly diagnosed multiple myeloma receiving D-VRd.

Findings from the phase 3 IMROZ trial support the FDA approval of the combination therapy for newly diagnosed not eligible for ASCT multiple myeloma.

Pluta Cancer Center clinicians discussed how to improve sexual health outcomes for patients diagnosed with gynecological cancer.

Results from the MARIPOSA-2 trial led to the approval of amivantamab plus chemotherapy in patients with EGFR-mutated NSCLC.

Results from the NATALEE trial of ribociclib/NSAI vs NSAI alone support the approval for patients with HR-positive, HER2-negative early breast cancer.

NO-CUT trial data show that DRFS was maintained when non-operative management was used in patients with pMMR locally advanced rectal cancer.

Follow-up data show breastfeeding to be feasible among patients with hormone receptor–positive breast cancer during an endocrine therapy break.

Patients with NSCLC across various subgroups did not see a disease-free survival benefit with adjuvant durvalumab compared with placebo.

Patients with certain solid tumors may be eligible for subcutaneous atezolizumab and hyaluronidase-tqjs, which is now approved by the FDA.

Patients with EGFR-mutated NSCLC had sustained HRQOL when treated with amivantamab plus lazertinib vs osimertinib.

HER2DX demonstrated the ability to select patients who are more likely to achieve disease control with anti-HER2 standard of care in the CLEOPATRA trial.

BAY 2927088 showed substantial response rates for patients with pretreated HER2-mutant non–small cell lung cancer.

Efficacy, safety, time, and cost were all factors assessed between subcutaneous and intravenous rituximab for patients with non-Hodgkin lymphoma.

A ready-to-use subcutaneous or intravenous injection of bortezomib for multiple myeloma and MCL has been approved by the FDA.

Cancer rehabilitation medicine may help bridge a gap in oncology care, according to Jessica Cheng, MD.

Second-line fruquintinib plus paclitaxel did not sustain sufficient efficacy for patients with advanced gastric or GEJ adenocarcinoma to support approval in China.

Trials assessing NSCLC and cutaneous squamous cell carcinoma were discontinued due to no benefit observed or improvement noted with the primary end points.

A watch-and-wait method was implemented when vitamin D was given prior to treatment for chronic lymphocytic leukemia.

A PDUFA date has been set for February 28, 2025, for the potential approval of mirdametinib in neurofibromatosis type 1-associated plexiform neurofibromas.

Improved overall survival was also noted when atezolizumab plus bevacizumab and FOLFOXIRI were used to treat patients with pMMR tumors.

Brentuximab vedotin plus chemotherapy significantly improved HRQOL in both pediatric and young adult patients with high-risk Hodgkin lymphoma.

The phase 1/2 LINKER-MM1 trial assessed linvoseltamab in relapsed/refractory multiple myeloma, of which the indication has been given a CRL by the FDA.